COURSE VIEWING REQUIREMENTS
|Supported Browsers: |
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above
For video playback, install the latest version of Flash or Quicktime.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Provider is approved by the California Board of Registered Nursing, Provider #13485, for 0.7 contact hours.
This educational activity for 0.7 contact hours is provided by Postgraduate Institute for Medicine.
This activity is also designated for 0.2 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Sandra E. Kurtin, MS, RN, ANP-C, AOCN®, reported a financial interest/relationship or affiliation in the form of: Advisory Board, Celgene Corporation, Incyte Corporation, Novartis Pharmaceuticals Corporation.
Sara M. Tinsley, PhDc, MS, ARNP, AOCN®, reported a financial interest/relationship or affiliation in the form of: Advisory Board, Amgen, Inc., Genentech, Inc.; Speakers' Bureau, Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Genentech, Inc., Incyte Corporation, Novartis Pharmaceuticals Corporation.
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Linda Gracie-King, MS and Diedrea White, BA, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
SAFEGUARDS AGAINST COMMERCIAL BIAS
Postgraduate Institute for Medicine and AXIS affirm that the content and format of its CME/CE activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including but not limited to review of all planned content for CME/CE activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education's and American Nurses Credentialing Center's Commission (ANCC) on Accreditation's content validation statements and resolution of any actual or perceived conflict of interest that exist. We employ three metrics as we review materials:
- Fair balance
- Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
- No single product or service is overrepresented when other equal competing products or services are available for inclusion
- Scientific objectivity of studies mentioned in the materials or used as the basis for content
- Appropriateness of patient care recommendations made to learners
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. METHOD OF PARTICIPATION
To receive acknowledgement of participation for this CME-certified activity, you must complete the evaluation and pass the posttest online with a score of 65% or better in a maximum of 5 attempts. You may print and/or download your certificate upon completion. ESTIMATED TIME TO COMPLETE ACTIVITY:
45 minutes FEE STATEMENT
There is no fee for this educational activity. CONTACT INFORMATION
To contact PIM, please visit www.pimed.com.
Supported through independent educational grants from Sanofi US and Incyte Corporation.